Comparison of wind roses between ERA5 reanalysis and in-situ measured data. a: W03 station, b: W08 station, c: W13 station and d: W19 station. by Weidong Ji (129916)

Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

Predictions of random forests (RF), gradient boosting machines (GBM), and neural networks (NN) trained on 12 covariates chosen using subjective feature selection. by Dennis Ochola (11626912)

Subjects:

Predictions of random forests (RF), gradient boosting machines (GBM), and neural networks (NN) trained on 17 covariates selected after recursive feature selection. by Dennis Ochola (11626912)

Subjects:

TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

S5 Fig - by Jordan K. Abbott (8934239)

The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: